Literature DB >> 366138

Levamisole in rheumatoid arthritis--a multivariate analysis of a multicentric study.

P J Lewi, J Symoens.   

Abstract

Statistical analysis of the data from a multicentric study of six months of treatment with levamisole in rheumatoid arthritis involved two steps. In a first step, the differences between observations before and after treatment have been made independent of their initial values. Differences after treatment have been transformed into responses to treatment using a proportionality factor that is related to the initial values before treatment. The second step involved a reduction of the various responses into a single global response by means of a discriminant analysis between two classes. Class membership has been defined by the type of treatment (either placebo or drug) predicted by the investigators at the end of treatment and before breaking of the code of the double-blind study. This method of analysis allows for the combination of multiple clinical observations with a subjective evaluation. Its results can be easily represented graphically and tested for statistical significance. The use of global responses to treatment is illustrated with a comparison of placebo and drug treatments and can be extended to comparisons between investigators or between different dose and time regimens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 366138

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  6 in total

1.  Follow-up with OM-8980 after a double-blind study of OM-8980 and auranofin in rheumatoid arthritis.

Authors:  T L Vischer
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

2.  A double blind multicentre study of OM-8980 and auranofin in rheumatoid arthritis.

Authors:  T L Vischer
Journal:  Ann Rheum Dis       Date:  1988-07       Impact factor: 19.103

3.  Levamisole in rheumatoid arthritis. Final report on a randomised double-blind study comparing a single weekly dose of levamisole with placebo. Multicentre Study Group.

Authors: 
Journal:  Ann Rheum Dis       Date:  1982-04       Impact factor: 19.103

4.  Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis.

Authors:  D R Swinson; J Zlosnick; L Jackson
Journal:  Ann Rheum Dis       Date:  1981-06       Impact factor: 19.103

5.  Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil.

Authors:  R F Holcombe; R M Stewart; K W Betzing; K Kannan
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

6.  Clinical response to therapy with thymopoietin pentapeptide (TP-5) in rheumatoid arthritis.

Authors:  E M Veys; E C Huskisson; M Rosenthal; T L Vischer; H Mielants; P A Thrower; J Scott; H Ott; H Scheijgrond; J Symoens
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.